Health TidingsNovo Nordisk Files Semaglutide Lawsuit Against Hims Novo Nordisk Files Semaglutide Lawsuit Against Hims Read Post »
Health TidingsEisai and Biogen Secure Priority Review in China for Subcutaneous LEQEMBI Eisai and Biogen Secure Priority Review in China for Subcutaneous LEQEMBI Read Post »
Health TidingsSanofi’s Rilzabrutinib Gains FDA Breakthrough Therapy Designation, Ja... Sanofi’s Rilzabrutinib Gains FDA Breakthrough Therapy Designation, Ja... Read Post »
Food Health TidingsUK Probes 36 Infant Illness Reports Linked to Recalled Infant Formula UK Probes 36 Infant Illness Reports Linked to Recalled Infant Formula Read Post »
Health TidingsFrom Launch to Halt: Hims & Hers’ Semaglutide Reversal From Launch to Halt: Hims & Hers’ Semaglutide Reversal Read Post »
Health TidingsPfizer Backs TrumpRx, Reduce Drug Prices in the U.S. Pfizer Backs TrumpRx, Reduce Drug Prices in the U.S. Read Post »
Health TidingsFibrobiologics Fetches Canadian Patent for Cachexia in Chronic Diseases Fibrobiologics Fetches Canadian Patent for Cachexia in Chronic Diseases Read Post »
Health TidingsTrumpRx.gov Goes Live, Drug Pricing and Policy in One Platform TrumpRx.gov Goes Live, Drug Pricing and Policy in One Platform Read Post »
Health TidingsEisai and Biogen Report Growing Real-World Use of Leqembi in Early Alzheime... Eisai and Biogen Report Growing Real-World Use of Leqembi in Early Alzheime... Read Post »
Health TidingsFDA Takes Aim at Non-Approved Compounded GLP-1 Drugs FDA Takes Aim at Non-Approved Compounded GLP-1 Drugs Read Post »
Health TidingsNovo Nordisk Accuses Hims & Hers of Illegal Semaglutide Compounding, Ci... Novo Nordisk Accuses Hims & Hers of Illegal Semaglutide Compounding, Ci... Read Post »
Health TidingsBMS and J&J Rethink Anticoagulation with Factor Xia BMS and J&J Rethink Anticoagulation with Factor Xia Read Post »
Health TidingsSimcere Doses First Patient in Anti-Stroke SIM0811 Trial Simcere Doses First Patient in Anti-Stroke SIM0811 Trial Read Post »
Health TidingsEli Lilly Q4 2025: Mounjaro and Zepbound Fuel 43% Growth Eli Lilly Q4 2025: Mounjaro and Zepbound Fuel 43% Growth Read Post »
Health TidingsValneva and Butantan Start IXCHIQ Chikungunya Vaccination Pilot in Brazil Valneva and Butantan Start IXCHIQ Chikungunya Vaccination Pilot in Brazil Read Post »
Health TidingsNovo Nordisk Reports 10% Sales Growth in 2025 as Wegovy Pill Launch Strengt... Novo Nordisk Reports 10% Sales Growth in 2025 as Wegovy Pill Launch Strengt... Read Post »
Health TidingsSPARC’s Sezaby Approval Unlocks Rare Pediatric Priority Review Voucher SPARC’s Sezaby Approval Unlocks Rare Pediatric Priority Review Voucher Read Post »
Health TidingsAstraZeneca Faces FDA Delay for At-Home Saphnelo SC in SLE AstraZeneca Faces FDA Delay for At-Home Saphnelo SC in SLE Read Post »
Health TidingsFDA Issues Complete Response Letter for Anaphylm Sublingual Epinephrine Fil... FDA Issues Complete Response Letter for Anaphylm Sublingual Epinephrine Fil... Read Post »
Health TidingsFDA Issues CRL for Pharming’s Joenja in Pediatric APDS Patients FDA Issues CRL for Pharming’s Joenja in Pediatric APDS Patients Read Post »
Health TidingsCARDAMYST™ Now Available in U.S. Pharmacies: A New Self-Administered Opti... CARDAMYST™ Now Available in U.S. Pharmacies: A New Self-Administered Opti... Read Post »
Health TidingsUltrahuman Partners With Click Therapeutics to Transform Migraine Managemen... Ultrahuman Partners With Click Therapeutics to Transform Migraine Managemen... Read Post »
Drugs Safety Alert Health TidingsFDA Issues Warning Letter to Telangana’s Palamur Biosciences Over GLP Ris... FDA Issues Warning Letter to Telangana’s Palamur Biosciences Over GLP Ris... Read Post »
Health TidingsJapan Honors Daiichi Sankyo with Prime Minister’s Award for EZHARMIA, the... Japan Honors Daiichi Sankyo with Prime Minister’s Award for EZHARMIA, the... Read Post »
Health TidingsAquestive Therapeutics Reports FDA-Identified Deficiencies in Anaphylm NDA,... Aquestive Therapeutics Reports FDA-Identified Deficiencies in Anaphylm NDA,... Read Post »
Health TidingsFDA Issues Complete Response Letter for Atara’s EBVALLO in EBV-Positive P... FDA Issues Complete Response Letter for Atara’s EBVALLO in EBV-Positive P... Read Post »
Health TidingsNestlé Baby Formula Recall 2026: What We Know About the Recall & Cereu... Nestlé Baby Formula Recall 2026: What We Know About the Recall & Cereu... Read Post »
Health TidingsVanda Therapeutics Receives Second FDA CRL for HETLIOZ in Jet Lag Disorder ... Vanda Therapeutics Receives Second FDA CRL for HETLIOZ in Jet Lag Disorder ... Read Post »
Health Tidings ResearchAbbott Launches Libre Assist in Libre App to Improve In-the-Moment Food Dec... Abbott Launches Libre Assist in Libre App to Improve In-the-Moment Food Dec... Read Post »
Health TidingsWegovy Pill Now Available in the U.S.: First Oral GLP-1 Weight-Loss Medicin... Wegovy Pill Now Available in the U.S.: First Oral GLP-1 Weight-Loss Medicin... Read Post »
Health Tidings ResearchFDA Issues Third CRL for Outlook Therapeutics’ ONS-5010/LYTENAVA in W... FDA Issues Third CRL for Outlook Therapeutics’ ONS-5010/LYTENAVA in W... Read Post »
Health Tidings ResearchCorcept Therapeutics Receives FDA Complete Response Letter for Relacorilant... Corcept Therapeutics Receives FDA Complete Response Letter for Relacorilant... Read Post »
Health TidingsNovo Nordisk Wins Final Patent Ruling on Semaglutide in China Novo Nordisk Wins Final Patent Ruling on Semaglutide in China Read Post »
Health Tidings ResearchGenmab Halts Clinical Development of Acasunlimab After Portfolio Review, Sh... Genmab Halts Clinical Development of Acasunlimab After Portfolio Review, Sh... Read Post »
Health TidingsEnvafolimab Granted FDA Orphan Drug Designation for Gastric and GEJ Cancer:... Envafolimab Granted FDA Orphan Drug Designation for Gastric and GEJ Cancer:... Read Post »
Health TidingsFDA Issues CRL for Sanofi’s Tolebrutinib in Non-Relapsing Secondary Progr... FDA Issues CRL for Sanofi’s Tolebrutinib in Non-Relapsing Secondary Progr... Read Post »
Health TidingsIpsen licenses SIM0613 ADC from Simcere Zaiming, targeting Phase I in 2026 Ipsen licenses SIM0613 ADC from Simcere Zaiming, targeting Phase I in 2026 Read Post »
Health TidingsJ&J Supports HRS Registry to Advance PFA Evidence in AFib J&J Supports HRS Registry to Advance PFA Evidence in AFib Read Post »
Health Tidings ResearchFDA Grants Advanced Manufacturing Technology Designation to Astellas’ Mah... FDA Grants Advanced Manufacturing Technology Designation to Astellas’ Mah... Read Post »
Health Tidings ResearchBlueRock Therapeutics’ Bemdaneprocel Earns Pioneering Regenerative Medica... BlueRock Therapeutics’ Bemdaneprocel Earns Pioneering Regenerative Medica... Read Post »
Health Tidings ResearchNo Patient Identifiers Needed: FDA Removes a Key Barrier to Using Real-Worl... No Patient Identifiers Needed: FDA Removes a Key Barrier to Using Real-Worl... Read Post »
Health Tidings ResearchFDA Moves Toward Real-World Evaluation of Digital Devices With TEMPO Progra... FDA Moves Toward Real-World Evaluation of Digital Devices With TEMPO Progra... Read Post »
Health Tidings ResearchAbbott Launches Two New Ensure® Max Protein Shakes: 42g Protein and 2-in-1... Abbott Launches Two New Ensure® Max Protein Shakes: 42g Protein and 2-in-1... Read Post »
Health Tidings ResearchEli Lilly Lowers Single-Dose Zepbound Vial Prices Eli Lilly Lowers Single-Dose Zepbound Vial Prices Read Post »
Clinical Trails Health TidingsAlexion Advances ALXN2420 to Phase 2: PeptiDream Unlocks Acromegaly Milesto... Alexion Advances ALXN2420 to Phase 2: PeptiDream Unlocks Acromegaly Milesto... Read Post »
Health Tidings ResearchEli Lilly Hits $1 Trillion Market Cap: How Mounjaro and Zepbound Revolution... Eli Lilly Hits $1 Trillion Market Cap: How Mounjaro and Zepbound Revolution... Read Post »
Health TidingsFDA Approves CAPLYTA® (Lumateperone) as Adjunctive Therapy for Major Depre... FDA Approves CAPLYTA® (Lumateperone) as Adjunctive Therapy for Major Depre... Read Post »
Health Tidings ResearchNovo Nordisk and Emcure Join Forces to Expand Semaglutide Market in India w... Novo Nordisk and Emcure Join Forces to Expand Semaglutide Market in India w... Read Post »
Health TidingsFDA Rejects Biohaven’s Vyglxia for Spinocerebellar Ataxia Citing External... FDA Rejects Biohaven’s Vyglxia for Spinocerebellar Ataxia Citing External... Read Post »
Health TidingsDupixent® (Dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechno... Dupixent® (Dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechno... Read Post »
